GlassScriptPhysician profile
Collene D Rogers
NPI 1053053389
$9,011.50
in general payments reported to CMS, 2019-2025
55 companies · $2,474 in 2025
The $2,474 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $673 · 2023: $2,678 · 2024: $3,187 · 2025: $2,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,699 · Education: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,698.80 |
| Education | $640.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,025.48 | 2022-2025 | Lynparza, Tagrisso, Imfinzi |
| Janssen Biotech, INC. | $703.86 | 2022-2025 | Rybrevant, Carvykti, Darzalex |
| Incyte Corporation | $512.29 | 2023-2025 | Zynyz, Niktimvo, Monjuvi |
| Lilly USA, LLC | $426.96 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $364.84 | 2022-2025 | |
| Daiichi Sankyo INC. | $325.81 | 2023-2025 | Enhertu |
| Beigene USA, INC. | $317.12 | 2022-2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $303.24 | 2023-2025 | |
| Genzyme Corporation | $262.29 | 2022-2024 | |
| Glaxosmithkline, LLC. | $241.31 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Exelixis INC. | $232.66 | 2023-2024 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $230.53 | 2023-2024 | Fruzaqla, Ninlaro |
| Emd Serono, INC. | $227.07 | 2024 | |
| Genentech USA, INC. | $189.47 | 2023 | Phesgo, Kadcyla, Perjeta |
| Bayer Healthcare Pharmaceuticals INC. | $177.18 | 2023-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $170.30 | 2022-2023 | Tukysa, Padcev, Adcetris |
| Sanofi-Aventis U.S. LLC | $169.98 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $166.17 | 2022-2024 | Libtayo |
| Pharmaessentia USA Corporation | $155.73 | 2023-2024 | Besremi |
| Sobi, INC | $146.60 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.12 | 2022-2024 | Gilotrif |
| Stemline Therapeutics INC. | $138.96 | 2024 | Elzonris, Orserdu |
| Beone Medicines USA, INC. | $138.17 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $134.90 | 2024 | |
| Geron Corporation | $125.00 | 2025 | Rytelo |
| Eisai INC. | $122.65 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $119.91 | 2022-2024 | Onivyde, Somatuline Depot, Tazverik |
| Genentech, INC. | $119.70 | 2023 | |
| Immunocore Limited | $117.99 | 2025 | Kimmtrak |
| Novartis Pharmaceuticals Corporation | $116.76 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $105.52 | 2024 | Monoferric, Cosela |
| Mirati Therapeutics, INC. | $105.13 | 2023 | Krazati |
| Agios Pharmaceuticals, INC. | $101.29 | 2023 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $97.97 | 2025 | Opdivo |
| Syndax Pharmaceuticals, INC. | $95.67 | 2025 | Revuforj |
| Uswm, LLC | $91.89 | 2025 | Tecelra |
| Pfizer INC. | $83.39 | 2023-2024 | |
| Emmaus Medical, INC. | $80.96 | 2022-2023 | Endari |
| Rigel Pharmaceuticals, INC. | $80.48 | 2022-2024 | Tavalisse, Rezlidhia |
| Progenics Pharmaceuticals, INC. | $77.68 | 2024 | |
| Aveo Pharmaceuticals, INC. | $64.51 | 2023-2024 | Fotivda |
| Adc Therapeutics America, INC. | $58.93 | 2023 | |
| Alnylam Pharmaceuticals INC. | $54.92 | 2023-2024 | Givlaari |
| Celgene Corporation | $41.03 | 2024-2025 | Reblozyl |
| Amgen INC. | $35.44 | 2022-2023 | Kyprolis |
| G1 Therapeutics, INC. | $31.64 | 2022-2023 | Cosela |
| Puma Biotechnology, INC. | $30.70 | 2024 | |
| Axonics, INC. | $23.73 | 2024 | Axonics |
| Verity Pharmaceuticals INC. | $22.47 | 2023 | Trelstar |
| Recordati_rare_diseases_inc. | $22.17 | 2024 | Sylvant |
| Adaptive Biotechnologies Corporation | $17.29 | 2024 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $16.38 | 2023 | Odomzo, Yonsa |
| Karyopharm Therapeutics INC. | $16.35 | 2022 | |
| Taiho Oncology, INC. | $14.80 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $14.11 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collene Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.